

A Next Generation TAVR Valve for the Treatment of Severe Aortic Regurgitation

Michigan Medicine is now participating in a clinical trial for the JenaValve Pericardial TAVR System in the treatment of patients with severe aortic regurgitation.

Introducing JenaValve

The JenaValve Transcatheter Heart Valve consists of porcine pericardial tissue, which is mounted on a low-profile, self-expanding nitinol stent. The tissue is connected to flexible stent posts which reduce leaflet stress during the diastolic phase. The valve size range includes size 23, size 25, and size 27 for implantation in aortic annuli of 21 mm to 27 mm in diameter.

Transcatheter Heart Valve



Self-Expanding Nitinol Frame

- Supra-Annular Prosthesis
- Large-Cells Facilitate Coronary Access
- Available in (3) Sizes to Treat a Broad Range of Patients

Porcine Pericardial Tissue

- Jasmine™ Proprietary Tissue Treatment Solution

Patented JenaValve Locator Technology



- Aligns valve with Native Anatomy
- Locators Clip onto Native Leaflets to Form a Natural Seal

Sealing Ring

- 24 Diamond-Shaped Cells Provide Annular Conformability and Sealing
- Minimal Protrusion into Left Ventricular Outflow Tract (LVOT)

Key Design Features

One of the key design characteristics of the JenaValve Pericardial Transcatheter Heart Valve is its locator technology which enables the device to “Clip” onto the native aortic leaflets to secure the valve. This unique anchoring mechanism is critical for securing the THV to the native aortic valve and allows for anatomical alignment and seating in the absence of calcification that is present in stenotic valves.



For additional information, please contact our clinical study coordinator, Jessica Oakley, at 734-232-9051.

Study ID: HUM00162122 IRB: IRBMED Date Approved: 8/6/2020 Expiration Date: 9/4/2020

HUM00162122

